ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
원발성 골수섬유증 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 미래 성장에 기여하는 요인으로는 혁신적인 치료 파이프라인의 확장, 질병 진행을 변화시키는 치료법에 대한 수요 증가, 노인 인구의 발병률 증가, 복합 치료 접근 방식으로의 전환, 제약 및 생명공학 회사의 높은 수준의 투자 등이 있습니다. 주요 새로운 동향으로서는 정밀 약제 개발의 진전, 진단에 있어서의 차세대 시퀀싱(NGS)의 이용, 기술을 구사한 환자 모니터링 툴, 다제 병용 요법 레지멘의 진보, 골수 섬유증의 화상 진단법의 개선 등을 들 수 있습니다.
골수 섬유증의 유병률 증가는 향후 몇 년간의 원발성 골수섬유증 시장의 확대를 촉진할 것으로 예측됩니다. 하면 골수에 큰 흉터를 일으켜, 그 결과 심각한 빈혈, 피로, 쇠약, 비장 비대를 일으킵니다. 이 질환은 전 세계 인구의 고령화로 인해 점점 더 널리 퍼지고 있으며, 가장 일반적으로 60세 이상의 개인에게 영향을 미칩니다. 기대 수명이 증가함에 따라 진단된 사례의 수가 계속 증가하고 있습니다. National Institute for Health and Care Excellence는 영국에서 골수섬유증의 유병률은 10만명당 3.2명, 발병률은 10만명당 0.6명으로 보고했습니다.
원발성 골수섬유증 시장의 주요 진출기업은 증상을 더 잘 관리하고 질병의 진행을 늦추기 위해 Janus kinase 2(JAK2) 억제 정제와 같은 혁신적인 치료법의 개발을 강조합니다. 이러한 경구용 약물은 원발성 골수섬유증에서 과도한 혈액 세포 생성을 초래하는 비정상적인 신호 경로에 관여하는 JAK2 효소를 차단하여 작용합니다. 글락소스미스클라인 코리아(GSK Korea)는 골수섬유증의 새로운 치료인 Omjjara (momelotinib)를 발표했습니다. 이 경구 요법은 JAK1, JAK2, 액티빈 A 수용체 1형(ACVR1)을 표적으로 하며, 빈혈, 비장종, 피로 등의 증상을 효과적으로 치료합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 원발성 골수섬유증 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 원발성 골수섬유증 시장 : 성장률 분석
세계의 원발성 골수섬유증 시장 실적 : 규모와 성장, 2019-2024년
세계의 원발성 골수섬유증 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 원발성 골수섬유증 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 원발성 골수섬유증 시장 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
척수 소뇌 원발성 골수섬유증
원발성 골수섬유증 모세 혈관 확대증
에피소드성 원발성 골수섬유증
기타
세계의 원발성 골수섬유증 시장 : 서비스별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
치료
진단
세계의 원발성 골수섬유증 시장 : 제형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
고체
액체
기타
세계의 원발성 골수섬유증 시장 : 연령층별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
성인
유아
고령자
세계의 원발성 골수섬유증 시장 : 최종사용자별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
병원
클리닉
기타
세계의 원발성 골수섬유증 시장 : 척수 소뇌 원발성 골수섬유증 병형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
척수 소뇌 실조증과 골수 섬유증
유전성 척수 소뇌 변성증(골수 섬유증 동반)
섬유화를 수반하는 신경 변성 척수 소뇌 증후군
세계의 원발성 골수섬유증 시장 : 원발성 골수섬유증 모세 혈관 확대증별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
골수 섬유증을 동반한 피부 모세 혈관 확대증
유전성 출혈성 모세 혈관 확대증과 골수 섬유증
안모세혈관확대증 관련 골수섬유증
세계의 원발성 골수섬유증 시장 : 에피소드성 원발성 골수섬유증 병형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
간헐성 골수 섬유증 에피소드
섬유화의 악화를 수반하는 주기성 혈구 감소증
자가면역 질환에서 주기성 골수 섬유증
세계의 원발성 골수섬유증 시장 : 그 밖의 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
가족성 원발성 골수섬유증
특발성 골수 섬유증
테라피 관련 원발성 골수섬유증
청소년 원발성 골수섬유증
제7장 지역별/국가별 분석
세계의 원발성 골수섬유증 시장 :지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 원발성 골수섬유증 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
원발성 골수섬유증 시장 : 경쟁 구도
원발성 골수섬유증 시장 : 기업 프로파일
Merck & Co. Inc.
AbbVie Inc.
Bristol-Myers Squibb Company
Sumitomo Pharma Oncology Inc.
Incyte Corporation
제31장 기타 주요 기업 및 혁신 기업
Nippon Shinyaku Co. Ltd.
MorphoSys AG
Keros Therapeutics Inc.
Geron Corporation
Lynk Pharmaceuticals Co. Ltd.
Pharmaxis Ltd
Kartos Therapeutics Inc.
Disc Medicine Inc.
Galecto Inc.
Cellenkos Inc.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
Taiga BIoTechnologies Inc.
Suzhou Zelgen Biopharmaceuticals Co. Ltd.
Telios Pharma Inc.
Samus Therapeutics Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 전략
원발성 골수섬유증 시장, 2029년 : 새로운 기회를 제공하는 국가
원발성 골수섬유증 시장, 2029년 : 새로운 기회를 제공하는 부문
원발성 골수섬유증 시장, 2029년 : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제36장 부록
SHW
영문 목차
영문목차
Primary myelofibrosis (PMF) is a rare and chronic bone marrow condition marked by the excessive development of fibrous scar tissue (fibrosis) within the bone marrow. This fibrosis interferes with the normal production of blood cells, resulting in symptoms such as anemia, fatigue, weakness, and an enlarged spleen (splenomegaly). PMF falls under the category of myeloproliferative neoplasms (MPNs) and can also lead to issues like night sweats, unintended weight loss, and bone discomfort.
The major types of primary myelofibrosis include spinocerebellar primary myelofibrosis, primary myelofibrosis-telangiectasia, episodic primary myelofibrosis, and other less common forms. Services provided encompass both diagnosis and treatment, while medication options are offered in multiple dosage forms, including solids, liquids, and other formulations, to cater to various patient needs. This condition can affect individuals of all age groups-children, adults, and the elderly-and is managed in various healthcare environments such as hospitals, clinics, and other care facilities.
The primary myelofibrosis market research report is one of a series of new reports from The Business Research Company that provides primary myelofibrosis market statistics, including the primary myelofibrosis industry global market size, regional shares, competitors with the primary myelofibrosis market share, detailed primary myelofibrosis market segments, market trends, and opportunities, and any further data you may need to thrive in the primary myelofibrosis industry. These primary myelofibrosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The primary myelofibrosis market size has grown strongly in recent years. It will grow from $0.79 billion in 2024 to $0.84 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. Growth during the historic period was driven by greater awareness of the disease among healthcare providers, expanded use of JAK inhibitors, improved diagnostic and genetic testing capabilities, enhanced access to hematology care, and a rise in clinical research activity.
The primary myelofibrosis market size is expected to see strong growth in the next few years. It will grow to $1.07 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. Contributing factors to future growth include the expansion of innovative treatment pipelines, rising demand for therapies that alter disease progression, increasing incidence among elderly populations, a shift toward combination treatment approaches, and higher levels of investment from pharmaceutical and biotechnology companies. Key emerging trends include progress in precision drug development, the use of next-generation sequencing (NGS) in diagnostics, tech-enabled patient monitoring tools, advancements in multi-drug therapy regimens, and improvements in imaging methods for bone marrow fibrosis.
The growing prevalence of myelofibrosis is anticipated to drive the expansion of the primary myelofibrosis market in the coming years. Myelofibrosis is a rare bone marrow cancer that interferes with the normal production of blood cells, leading to significant scarring in the bone marrow, which in turn causes severe anemia, fatigue, weakness, and an enlarged spleen. This condition is increasingly prevalent due to the aging global population, as it most commonly affects individuals over the age of 60. With life expectancy on the rise, the number of diagnosed cases continues to grow. This increase in prevalence supports advancements in primary myelofibrosis management by promoting research, encouraging early diagnosis, expanding treatment options, and refining clinical guidelines and care strategies. For example, in November 2024, the National Institute for Health and Care Excellence, a UK-based independent executive non-departmental public body, reported that myelofibrosis has a prevalence of 3.2 per 100,000 people in the UK and an incidence rate of 0.6 per 100,000. As a result, the increasing number of cases is contributing to the growth of the primary myelofibrosis market.
Key players in the primary myelofibrosis market are emphasizing the development of innovative treatments such as Janus kinase 2 (JAK2) inhibiting tablets to better manage symptoms and slow disease progression. These oral medications work by blocking the JAK2 enzyme, which is involved in abnormal signaling pathways that result in excessive blood cell production in primary myelofibrosis. JAK2 inhibitors help reduce spleen size, relieve fatigue and bone pain, and slow disease progression. For instance, in March 2025, GlaxoSmithKline Korea (GSK Korea) Ltd., a pharmaceutical and biotechnology company based in South Korea, introduced Omjjara (momelotinib), a new treatment for myelofibrosis. Approved by South Korea's Ministry of Food and Drug Safety, Omjjara is designed for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who suffer from moderate to severe anemia. This oral therapy targets JAK1, JAK2, and activin A receptor type 1 (ACVR1), effectively treating symptoms such as anemia, splenomegaly, and fatigue. Clinical trial results showed significant improvements in these areas compared to existing treatments, supporting the drug's approval.
In June 2022, GSK plc, a UK-based pharmaceutical and biotechnology firm, completed the acquisition of Sierra Oncology, Inc. for approximately $1.9 billion. This move was intended to strengthen GSK's oncology pipeline, particularly in the area of hematologic cancers. Sierra Oncology, Inc. is a U.S.-based biopharmaceutical company focused on the development of therapies for primary myelofibrosis.
Major players in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd.
North America was the largest region in the primary myelofibrosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in primary myelofibrosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the primary myelofibrosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary myelofibrosis market consists of revenues earned by entities by providing services such as diagnosis services, medical consultations, treatment services, monitoring and follow-up and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary myelofibrosis (PMF) market also includes sales of products including ruxolitinib (Jakafi or Jakavi), erythropoiesis-stimulating agents (ESAs), hydroxyurea, bone marrow or stem cell transplant kits and iron supplements. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Primary Myelofibrosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on primary myelofibrosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for primary myelofibrosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The primary myelofibrosis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Spinocerebellar Primary Myelofibrosiss; Primary Myelofibrosis-Telangiectasia; Episodic Primary Myelofibrosis; Other Types
2) By Services: Treatment; Diagnosis
3) By Dosage Forms: Solid; Liquids; Other Dosage Forms
4) By Age: Adult; Child; Geriatric
5) By End User: Hospitals; Clinics; Other End Users
Subsegments:
1) By Spinocerebellar Primary Myelofibrosis: Spinocerebellar Ataxia With Myelofibrosis; Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis; Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations
2) By Primary Myelofibrosis-Telangiectasia: Cutaneous Telangiectasia With Myelofibrosis; Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis; Ocular Telangiectasia-Associated Myelofibrosis
3) By Episodic Primary Myelofibrosis: Intermittent Marrow Fibrosis Episodes; Periodic Cytopenia With Fibrosis Flare; Cyclical Myelofibrosis In Autoimmune Disorders
4) By Other Types: Familial Primary Myelofibrosis; Idiopathic Myelofibrosis; Therapy-Related Primary Myelofibrosis; Juvenile Primary Myelofibrosis
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Primary Myelofibrosis Market Characteristics
3. Primary Myelofibrosis Market Trends And Strategies
4. Primary Myelofibrosis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Primary Myelofibrosis Growth Analysis And Strategic Analysis Framework
5.1. Global Primary Myelofibrosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Primary Myelofibrosis Market Growth Rate Analysis
5.4. Global Primary Myelofibrosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Primary Myelofibrosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Primary Myelofibrosis Total Addressable Market (TAM)
6. Primary Myelofibrosis Market Segmentation
6.1. Global Primary Myelofibrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Spinocerebellar Primary Myelofibrosiss
Primary Myelofibrosis-Telangiectasia
Episodic Primary Myelofibrosis
Other Types
6.2. Global Primary Myelofibrosis Market, Segmentation By Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Treatment
Diagnosis
6.3. Global Primary Myelofibrosis Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Solid
Liquids
Other Dosage Forms
6.4. Global Primary Myelofibrosis Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adult
Child
Geriatric
6.5. Global Primary Myelofibrosis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Other End Users
6.6. Global Primary Myelofibrosis Market, Sub-Segmentation Of Spinocerebellar Primary Myelofibrosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Spinocerebellar Ataxia With Myelofibrosis
Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis
Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations
6.7. Global Primary Myelofibrosis Market, Sub-Segmentation Of Primary Myelofibrosis-Telangiectasia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cutaneous Telangiectasia With Myelofibrosis
Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis
Ocular Telangiectasia-Associated Myelofibrosis
6.8. Global Primary Myelofibrosis Market, Sub-Segmentation Of Episodic Primary Myelofibrosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intermittent Marrow Fibrosis Episodes
Periodic Cytopenia With Fibrosis Flare
Cyclical Myelofibrosis In Autoimmune Disorders
6.9. Global Primary Myelofibrosis Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Familial Primary Myelofibrosis
Idiopathic Myelofibrosis
Therapy-Related Primary Myelofibrosis
Juvenile Primary Myelofibrosis
7. Primary Myelofibrosis Market Regional And Country Analysis
7.1. Global Primary Myelofibrosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Primary Myelofibrosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
